Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR

[Display omitted] EZH2 (enhancer of zeste homologue 2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2) that catalyzes the methylation of lysine 27 of histone H3 (H3K27). Dysregulation of EZH2 activity is associated with several human cancers and therefore EZH2 inhibition has eme...

Full description

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry letters Vol. 27; no. 2; pp. 217 - 222
Main Authors Ansari, Amantullah, Satalkar, Sharad, Patil, Varshavekumar, Shete, Amit S., Kaur, Simranjeet, Gupta, Ashu, Singh, Siddhartha, Raja, Mohd, Severance, Daniel L., Bernales, Sebastián, Chakravarty, Sarvajit, Hung, David T., Pham, Son M., Herrera, Francisco J., Rai, Roopa
Format Journal Article
LanguageEnglish
Published OXFORD Elsevier Ltd 15.01.2017
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:[Display omitted] EZH2 (enhancer of zeste homologue 2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2) that catalyzes the methylation of lysine 27 of histone H3 (H3K27). Dysregulation of EZH2 activity is associated with several human cancers and therefore EZH2 inhibition has emerged as a promising therapeutic target. Several small molecule EZH2 inhibitors with different chemotypes have been reported in the literature, many of which use a bicyclic heteroaryl core. Herein, we report the design and synthesis of EZH2 inhibitors containing an indoline core. Partial saturation of an indole to an indoline provided lead compounds with nanomolar activity against EZH2, while also improving solubility and oxidative metabolic stability.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2016.11.080